UK Alzheimer’s Disease Drugs Market Analysis

UK Alzheimer’s Disease Drugs Market Analysis


$ 3999

The UK Alzheimer’s disease drugs market was valued at $401 Mn in 2022 and is estimated to expand at a CAGR of 6.42% from 2022-30 and will reach $660 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are AbbVie, AstraZeneca, Accord Healthcare, Aesica Queenborough, Allen & Hanburys, Biogen, Daiichi Sankyo Company, Eisai Co., Eli Lilly and Company, Johnson and Johnson, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, Ono Pharmaceutical Co., Pfizer and Teva Pharmaceutical among others.

ID: IN10GBPH006 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Nandini Shah

Buy Now

UK Alzheimer’s Disease Drugs Market Executive Summary

The UK Alzheimer’s Disease Drugs market was valued at $401 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 6.42% from 2022 to 2030 and will reach $660 Mn in 2030. Alzheimer's disease is a degenerative neurological ailment that impairs the ability of the brain to operate normally. Alzheimer's disease symptoms often begin with modest memory loss and difficulties with language and communication. Patients may experience progressively severe memory loss, confusion, and trouble with daily activities as the condition develops. Alzheimer's disease is eventually fatal, with patients typically living 4 to 8 years after symptoms appear.

According to Alzheimer's Society, 2019, there were approximately 850,000 persons in the UK with dementia in 2019. This equates to one in every 14 of the population aged 65 and up. At the present rate of prevalence, the UK will have almost 1.5 Mn people with dementia by 2040.

UK alzheimers disease drugs market analysis

Market Dynamics

Market Growth Drivers

Alzheimer's disease is a progressive neurological disorder that primarily affects older adults, and the prevalence of the disease is increasing globally due to the aging population. In the UK, it is estimated that around 850,000 people are living with dementia, with Alzheimer's disease being the most common form. As the number of people affected by Alzheimer's disease continues to rise, the demand for drugs to treat the disease is expected to increase as well. There has been a significant amount of research and development in the field of Alzheimer's disease, with several promising drugs in the pipeline. For example, there are ongoing clinical trials of drugs that target amyloid beta, a protein that forms plaques in the brains of people with Alzheimer's disease. If these drugs are successful, they could provide new patient treatment options and drive growth in the Alzheimer's drugs market.

The UK government has launched several initiatives aimed at improving the care and treatment of people with Alzheimer's disease. For example, the government's National Dementia Strategy aims to improve early diagnosis and access to treatment for people with dementia, including Alzheimer's disease. These initiatives could help to increase the demand for Alzheimer's drugs and drive growth in the market. There is growing awareness of Alzheimer's disease and its impact on individuals and society. This increased awareness could lead to more people seeking diagnosis and treatment for the disease, which could drive growth in the Alzheimer's drugs market.

Market Restraints

While there are several drugs available to treat Alzheimer's disease, these treatments are not effective for all patients, and there is no cure for the disease. This can be frustrating for patients and their families and can limit the growth of the Alzheimer's drugs market. The medications used to treat Alzheimer's disease can be costly, limiting some patients access to treatment. This can be especially difficult for patients without private health insurance or who do not qualify for government-funded treatment. The drug approval procedure in the United Kingdom can be lengthy and difficult, delaying the availability of novel Alzheimer's disease treatments. Furthermore, the National Institute for Health and Care Excellence (NICE) cost-effectiveness standards can limit the availability of particular pharmaceuticals. There is still a lot of stigma around Alzheimer's disease, which can make people afraid to seek diagnosis and treatment. Furthermore, there are still numerous misconceptions about the disease and its treatment, which can limit access to care and contribute to the issues that the Alzheimer's drug industry is facing.

Competitive Landscape

Key Players

  • Abbvie
  • AstraZeneca
  • Accord Healthcare
  • Biogen
  • Aesica Queenborough
  • Allen & Hanburys
  • Daiichi Sankyo Company
  • Eisai Co.
  • Eli Lilly and Company
  • H. Lundbeck A/S
  • Johnson and Johnson
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Pfizer

Healthcare Policies and Regulatory Landscape

The UK healthcare policy plays an important role in the availability, accessibility, and affordability of Alzheimer's drugs in the country. The policy framework for Alzheimer's drugs is governed by the National Institute for Health and Care Excellence (NICE) and the National Health Service (NHS). The NHS is responsible for providing healthcare services to the population of the UK, including the provision of Alzheimer's drugs. The NHS provides access to Alzheimer's drugs through the prescription system, where patients receive medication from a healthcare provider, or through hospital clinics. The availability of Alzheimer's drugs through the NHS is subject to cost-effectiveness criteria set by NICE. This means that drugs must be shown to be effective and cost-effective in order to be made available through the NHS.

The UK healthcare policy also places an emphasis on early diagnosis and intervention for Alzheimer's disease. The National Dementia Strategy, launched by the UK government in 2009, aims to improve the diagnosis, treatment, and care of people with dementia, including Alzheimer's disease. The strategy includes measures to improve early diagnosis and access to treatment for people with the disease.

Reimbursement Scenario

The reimbursement scenario for Alzheimer's drugs in the UK is governed by the National Institute for Health and Care Excellence (NICE), which evaluates the clinical and cost-effectiveness of medicines and issues guidance on their use. NICE evaluates drugs based on their clinical effectiveness and their cost-effectiveness. If a drug is deemed clinically effective, NICE will then consider its cost-effectiveness. The cost-effectiveness of a drug is determined by calculating its cost per Quality-adjusted Life Year (QALY) gained. QALY is a measure of the quantity and quality of life gained by a patient from treatment. If the cost per QALY gained is deemed to be within an acceptable range, NICE will recommend the drug for use by the National Health Service (NHS).

Drugs that NICE recommends are made available to patients through the NHS prescription system, where patients receive medication from a healthcare provider, or through hospital clinics.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Alzheimer's Disease Drugs Market Segmentation

By Drug Class (Revenue, USD Bn)

  • Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine)
  • N-Methyl-D-Aspartate (NMDA) Receptor Antagonists (Memantine)
  • Combination Drugs
  • Others (Lecanemab, Aducanumab)

Drug segmentation is the process of dividing a set of drugs into different categories or classes based on their pharmacological properties, therapeutic uses, and other characteristics. Here, Alzheimer’s Disease Drugs Market is segmented into Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Combination Drugs, and others like (Lecanemab, Aducanumab)

By Distribution Channel (Revenue, USD Bn)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Route of Administration

  • Oral
  • Transdermal
  • Intravenous

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 14 March 2023
Updated by: Keta Vora

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up